JP2023500574A5 - - Google Patents
Info
- Publication number
- JP2023500574A5 JP2023500574A5 JP2022520769A JP2022520769A JP2023500574A5 JP 2023500574 A5 JP2023500574 A5 JP 2023500574A5 JP 2022520769 A JP2022520769 A JP 2022520769A JP 2022520769 A JP2022520769 A JP 2022520769A JP 2023500574 A5 JP2023500574 A5 JP 2023500574A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acid
- chimeric molecule
- molecule according
- tmmp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962925115P | 2019-10-23 | 2019-10-23 | |
| US62/925,115 | 2019-10-23 | ||
| PCT/US2020/056908 WO2021081239A1 (en) | 2019-10-23 | 2020-10-22 | T-cell modulatory chimeric molecules and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023500574A JP2023500574A (ja) | 2023-01-10 |
| JP2023500574A5 true JP2023500574A5 (enExample) | 2023-10-25 |
Family
ID=75620861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520769A Pending JP2023500574A (ja) | 2019-10-23 | 2020-10-22 | Ｔ細胞調節性キメラ分子及びその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20230055644A1 (enExample) |
| EP (1) | EP4048689A4 (enExample) |
| JP (1) | JP2023500574A (enExample) |
| CN (1) | CN114599674A (enExample) |
| AU (1) | AU2020370292A1 (enExample) |
| CA (1) | CA3146917A1 (enExample) |
| IL (1) | IL290298A (enExample) |
| WO (1) | WO2021081239A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017201210A1 (en) * | 2016-05-18 | 2017-11-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| ES2973548T3 (es) | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
| EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF |
| US20200010528A1 (en) | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| JP2020534352A (ja) | 2017-09-07 | 2020-11-26 | キュー バイオファーマ，インコーポレーテッド | コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法 |
| CN111886241A (zh) | 2018-01-09 | 2020-11-03 | 库尔生物制药有限公司 | 多聚体t细胞调节多肽及其使用方法 |
| MX2021007479A (es) * | 2018-12-19 | 2021-09-23 | Cue Biopharma Inc | Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos. |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| JP2025511703A (ja) * | 2022-04-07 | 2025-04-16 | キュー バイオファーマ， インコーポレイテッド | 免疫細胞結合ポリペプチド |
| GB202205771D0 (en) * | 2022-04-20 | 2022-06-01 | Replay Holdings Llc | Methods and compositions for cellular therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2010107199A (ru) * | 2007-07-31 | 2011-09-10 | Дзе Джонс Хопкинс Юниверсити (Us) | Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений |
| US20170335281A1 (en) * | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| WO2015195531A2 (en) * | 2014-06-18 | 2015-12-23 | Albert Einstein College Of Medicine, Inc. | Syntac polypeptides and uses thereof |
| ES2973548T3 (es) * | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
| US20200010528A1 (en) * | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| JP2020534352A (ja) * | 2017-09-07 | 2020-11-26 | キュー バイオファーマ，インコーポレーテッド | コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法 |
-
2020
- 2020-10-22 CA CA3146917A patent/CA3146917A1/en active Pending
- 2020-10-22 WO PCT/US2020/056908 patent/WO2021081239A1/en not_active Ceased
- 2020-10-22 EP EP20878131.0A patent/EP4048689A4/en not_active Withdrawn
- 2020-10-22 CN CN202080064663.3A patent/CN114599674A/zh not_active Withdrawn
- 2020-10-22 JP JP2022520769A patent/JP2023500574A/ja active Pending
- 2020-10-22 AU AU2020370292A patent/AU2020370292A1/en active Pending
-
2022
- 2022-02-02 IL IL290298A patent/IL290298A/en unknown
- 2022-02-23 US US17/678,748 patent/US20230055644A1/en not_active Abandoned
-
2025
- 2025-09-12 US US19/327,171 patent/US20260070959A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023500574A5 (enExample) | ||
| JP2023500573A5 (enExample) | ||
| JP2022534846A5 (enExample) | ||
| JP2025037871A5 (enExample) | ||
| CN110785435B (zh) | 与il-12和il-18的基于il-15的融合物 | |
| JP2023518049A5 (enExample) | ||
| JP2021536265A5 (enExample) | ||
| KR102528977B1 (ko) | 펩타이드-hla 복합체 및 그 제조 방법 | |
| JP2021525509A5 (enExample) | ||
| EP3169703B1 (en) | Chimeric antigen receptor and its use | |
| JP2022515331A5 (enExample) | ||
| Fremont et al. | Biophysical studies of T-cell receptors and their ligands | |
| JP2019518424A5 (enExample) | ||
| NZ759969A (en) | Tagged chimeric effector molecules and receptors thereof | |
| JP2022552314A5 (enExample) | ||
| FI3909972T3 (fi) | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä | |
| JP2017504601A5 (enExample) | ||
| JP2018525006A5 (enExample) | ||
| KR20180057720A (ko) | 다가 Fv 항체 | |
| JP2018525033A5 (enExample) | ||
| JP2022536581A5 (enExample) | ||
| JP2017501702A5 (enExample) | ||
| JP2019535262A5 (enExample) | ||
| RU2015129640A (ru) | Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1 | |
| JP2021534740A5 (enExample) |